Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AHPA’s new VP

This article was originally published in The Tan Sheet

Executive Summary

Former Nutricia exec Steven Dentali, PhD, will update AHPA's kava safety information guide as one of his first tasks with the trade association, which he joined March 5. Dentali assumes role of VP-scientific & technical affairs, previously held by Joseph Betz, PhD, who moved to NIH's Office of Dietary Supplements in January (1"The Tan Sheet" Dec. 17, 2001, p. 14). Dentali has been on AHPA's board since August 2000; he spent the last two years as senior director of botanical sciences at Nutricia, Royal Numico's U.S. research arm. Nutricia has no plans to replace Dentali at this time...

You may also be interested in...



AHPA board update

Susan Trimbo, Nutricia USA Senior VP-Scientific Affairs, replaces Steven Dentali, PhD, as Nutricia's rep on trade association's board of trustees. Dentali recently left Nutricia to take over as VP-Scientific & Technical affairs with AHPA (1"The Tan Sheet" March 11, 2002, p. 2). Trimbo is one of five newly elected members to the group's board; Nutraceutical Corp. VP-R&D James Selander will continue to serve as chairman...

ODS Methods, Reference Materials Program To Be Directed By AHPA’s Betz

Joseph Betz, PhD, is joining NIH's Office of Dietary Supplements to oversee a new program to facilitate development and validation of analytical methods and reference materials for dietary supplements

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel